First-In-Class Epilepsy Treatment Fycompa® (Perampanel) Now Available in Russia for Primary Generalised Tonic-Clonic Seizures

HATFIELD, England, December 8, 2015 /PRNewswire/ --


New anti-convulsant treatment to reduce serious seizures for idiopathic generalised

epilepsy, now available in Russia   

Fycompa(R) (perampanel), a convenient, once-daily epilepsy treatment, launches in Russia today, for primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (greater than or equal to12 years) with idiopathic generalised epilepsy (IGE). [1] The number of anti-epileptic drugs (AEDs) licensed for the treatment of PGTC seizures is limited[2] and as many as 20 percent (%) of people with idiopathic generalised epilepsy (IGE) remain uncontrolled, despite treatment.[3] Perampanel is the first new treatment for PGTC seizures in IGE in five years.[4]

There are approximately 496, 920 people in Russia with epilepsy; one third of these have idiopathic generalised epilepsy and approximately 60% of these (103,525 people), will experience PGTC seizures.[5],[6],[7] Perampanel offers clinicians a first-in-class treatment that reduces PGTC seizures, which are dangerous epileptic events.[8] These seizures increase the risk of injury, such as fractured bones, shoulder dislocation and burns.[9] PGTC seizures also increase the risk of sudden unexplained death in epilepsy (SUDEP) and are known to lead to atypical absence status epilepticus (ASE),[10] seizures that may last for extended time periods.

"Primary generalised tonic-clonic seizures can cause serious injuries and can even be fatal. The availability of perampanel, which reduces the frequency of seizures, is welcome news for Russian people aged 12 years and over and living with this form of epilepsy," comments Elena Belousova, Director of Psychoneurology and Epileptology, Moscow Research Institute of Paediatrics. 

Grand mal (PGTC) seizures start with a loss of consciousness and a sudden contraction of the muscles, which can cause the person to fall down (tonic phase). This is followed by violent convulsions (clonic phase) until the muscles finally relax.[11] While the seizure generally lasts a few minutes, the person will often feel confused or drowsy for up to a few minutes or up to a few hours, before returning to normal.[8]

Perampanel is the first-and-only licensed AED to selectively target the initiation and spread of seizures through inhibition of AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures.[12] Perampanel is also indicated for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.[1]

One third more patients experienced a reduction in seizure frequency with perampanel over 28 days versus placebo (50% responder rate 64.2% vs 39.5%, respectively; P=0.0019). [13] Perampanel demonstrates a reduction in PGTC seizure frequency (per 28 days) versus placebo (76.5% vs 38.4%, respectively; P4 years. (Rufinamide was originally developed by
- Zonegran(R) (zonisamide) as monotherapy in the treatment of partial seizures, with or
without secondary generalisation, in adults with newly diagnosed epilepsy and as
adjunctive therapy in the treatment of partial seizures, with or without
generalisation, in adults, adolescents and children aged six years and above.
(Zonegran is under license from the originator Dainippon Sumitomo Pharma).
- Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients with
partial onset seizures, with or without secondary generalisation. (Zebinix is under
license from BIAL).

About Eisai Co., Ltd.  

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology. 

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit


1. Fycompa Summary of Product Characteristics (SPC), Available at: Accessed June 2015

2. Rheims S and Ryvlin P. Exp Opin Pharmacother. 2014;15:1417-1426.

3. Faught E. Rev Neurol Dis 2004;1:S34-S43;

4. Eisai. Data on file. 2015

5. Panayiotopoulous CP, The Epilepsies: Seizures, Syndromes and Management. 2015. Bladan Medical Publishing

6. Hauser WA et al. Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935-1982. 1993. Epilepsia 34(3);453-468

7. Hauser WA et al. The epidemiology of epilepsy in the Russian Federation. Epilepsy Research (2010) Volume 92, Issues 2-3, Pages 209-218

8. Epilepsy Foundation. Types of seizures. Available at: Last Accessed May 2015

9. Asadi-Pooya AA et al. Seizure 2012;21:165-168.

10. IGE Summary. Epilepsy Foundation  Accessed June 2015

11. Epilepsy Action. Generalised seizures. Accessed May 2015

12. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents 2011;11:56-63.

13. French J et al. Adjunctive perampanel RCT for PGTC seizures. Association of British Neurologists annual meeting 2015; Abstract #53141

14. Eisai. Data on file. 2015

15. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224 - 2233.

Date of preparation: July 2015 
Job code: Fycompa-UK0211 



CONTACT: Media Enquiries: Eisai, Cressida Robson/Ben Speller, +44(0)7908314 155/+44(0)7908 409 416,, / Tonic Life Communications, Elisabeth Neal/DeepaPatel, +44(0) 07896 954 865/+44(0)7725 440 867,,

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234